Nano-TLZ

Nano-TLZ (Nano-Talazoparib) is a nano-liposomal formulation of the potent poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib. Developed by researchers at Michigan State University and Northeastern University, Nano-TLZ encapsulates talazoparib within the bilayer of a nano-liposome to improve its bioavailability, prolong circulation time, and enhance tumor accumulation via the enhanced permeability and retention (EPR) effect. This nanoformulation is designed to overcome the systemic toxicities (such as hematologic toxicities) and limited bioavailability associated with conventional oral talazoparib. Preclinical studies have demonstrated that Nano-TLZ significantly enhances therapeutic efficacy, induces DNA damage and cell cycle arrest, and favorably modulates the tumor immune microenvironment by reducing myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in BRCA-deficient breast and ovarian cancers, as well as Ewing sarcoma.

Other names

Nano-Talazoparibliposomal talazoparibnanoformulated talazoparibtalazoparib liposomal